Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune ...

Those who are more vulnerable to getting sick during a spring or summer surge may benefit from the new monoclonal antibody ...

Sean is originally from the Chicago area, but he got to the South as soon as he could. He loves the warm weather, friendly faces, and good food! After having bounced around the country several times, ...

Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the ...

Berlin Cures announced the successful completion of patient screening for its pan-European Phase II trial of BC 007, a novel therapeutic candidate for the treatment of Long COVID.

The following examines notable updates that occurred for investigational products in development in March 2024. The table below is a review of notable updates that occurred in March 2024 for ...

While the risks associated with COVID-19 generally have decreased over time due to prior exposure to the vaccines and ...

For some people who are immunocompromised, a newly authorized monoclonal antibody, Pemgarda, or pemivibart, may provide an additional layer of protection, Kotton said. These antibodies may substitute ...

For some people who are immunocompromised, a newly authorized monoclonal antibody, Pemgarda, or pemivibart, may provide an additional layer of protection, Kotton said. These antibodies may substitute ...

Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product administrationReimbursement through Medicare/Medicaid ...